Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free and University College London Medical School, London WC1E 6JF, UK
Auto-generated profile, based on publicly available information
Jeffrey W. Stephens
Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free and University College London Medical School, London WC1E 6JF, UK
Background Oxidative stress reduces total antioxidant status (TAOS) and is implicated in atherogenesis. Mitochondrial uncoupling protein 2 (UCP2) negatively regulates reactive oxygen species generation. The UCP2 gene demonstrates a common functional promoter variant (-866G>A). Methods and results Amongst 465 diabetic men (age 61.7±13.3 years), an association of the UCP2-866A allele with significantly lower TAOS in those without CHD was even more pronounced in those with CHD (TAOS 30.1±16.1% vs. 41.6±12.4% for AA vs. GG; \(P=0.016\) ). In a sample of 20 diabetic men selected for homozygosity for the UCP2-866G>A variant, matched for baseline characteristics, plasma markers of oxidative stress in those with CHD were significantly higher in AA genotype men (TAOS 31.7±7.3% vs. 52.6±6.3%; \(P=0.001\) and F2-isoprostanes 220.6±37.2 pg ml−1 vs. 109.9±51.1 pg ml−1; \(P=0.005\) for AA vs. GG). Amongst 2695 healthy men (age 56.1±3.5 years) prospectively studied for a median 10.2 years, AA homozygotes had a highly significant doubling in CHD risk after adjustment for established risk factors (HR 1.99 [1.37–2.90]; \(P=0.002\) ). Risk associated with this genotype was substantially increased by the presence of other risk factors (obesity, hypertension and diabetes). Conclusions This study provides the first in vivo evidence of a role for UCP2 in modifying oxidative stress and CHD risk in humans.
1 September 2006 in Journal of Diabetes and its Complications